<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="38833">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02600845</url>
  </required_header>
  <id_info>
    <org_study_id>RD002206</org_study_id>
    <nct_id>NCT02600845</nct_id>
  </id_info>
  <brief_title>ACCU-CHEK Connect Personal Diabetes Management Study (PDM CONNECT)</brief_title>
  <official_title>ACCU-CHEK Connect Personal Diabetes Management Study (PDM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Diabetes Care GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This post-market, interventional, prospective, single arm, the United States (US) based
      multi-center study will assess the change in treatment satisfaction of participants who
      utilize the ACCU-CHEK Connect Diabetes Management System over a period of 6 months.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 30, 2015</start_date>
  <completion_date type="Actual">February 20, 2017</completion_date>
  <primary_completion_date type="Actual">September 30, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Satisfaction: Change from Baseline to Week 24 in Diabetes Treatment Satisfaction Questionnaire (DTSQc) Score</measure>
    <time_frame>Baseline, Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 in Diabetes Distress Scale (DDS) Score</measure>
    <time_frame>Baseline, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants Preference for the ACCU-CHEK Connect Process as Assessed by Healthcare Providers (HCP) Questionnaire</measure>
    <time_frame>Baseline, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12 and 24</measure>
    <time_frame>Baseline, Week 12, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 in Percentage Glucose Target Range</measure>
    <time_frame>Baseline, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 in Mean Blood Glucose Level</measure>
    <time_frame>Baseline, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 in Glycemic Variability</measure>
    <time_frame>Baseline, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Hypoglycemia</measure>
    <time_frame>24 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 in Participants Self-monitoring of Blood Glucose (SMBG) Data Problem Solving Skill</measure>
    <time_frame>Baseline, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinician/staff Preference for the ACCU-CHEK Connect Process as Assessed by HCP Questionnaire</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of Structured Diabetes Data on Healthcare Practitioner's Informed Decision Regarding Participants Therapy Adjustment as Assessed by HCP Questionnaire</measure>
    <time_frame>24 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">125</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>ACCU-CHEK</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will utilize ACCU-CHEK Connect Diabetes Management System containing three primary component: ACCU-CHEK aviva connect blood glucose monitoring system intended to be used for the quantitative measurement of glucose, ACCU-CHEK connect diabetes management app indicated as an aid in the treatment of diabetes, and ACCU-CHEK connect online diabetes management system indicated for use by persons with diabetes or by healthcare professionals in the home or in healthcare facilities.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ACCU-CHEK AVIVA CONNECT</intervention_name>
    <description>ACCU-CHEK Connect Diabetes Management System contains ACCU-CHEK aviva connect blood glucose monitoring system, ACCU-CHEK connect diabetes management app, ACCU-CHEK connect online diabetes management system.</description>
    <arm_group_label>ACCU-CHEK</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of type 1 or type 2 diabetes for greater than or equal to (&gt;=) 6 months

          -  Currently using insulin as a component of the diabetes therapy

          -  Allow and be able to provide self-monitoring of blood glucose (SMBG) data at least 1
             month prior to study start

          -  SMBG frequency as confirmed by site SMBG data download of participants meter(s):
             Basal insulin treated participants - SMBG &gt;=5 times per week and Multiple dose
             insulin participants - SMBG &gt;=2 times per day

          -  Glycosylated hemoglobin (HbA1c) of &gt;=7.5 percentage (per local laboratory obtained
             less than or equal to [&lt;= 3] months of Baseline)

          -  Able to read and write in English language

          -  Currently using a Smartphone and have experience with downloading at minimum one
             application

          -  Smartphone compatibility; must be able to download the ACCU-CHEK Connect system
             application accordingly

          -  Naive to the ACCU-CHEK Connect system

          -  Willing to comply with study procedures

        Exclusion Criteria:

          -  Treatment with insulin pump therapy

          -  Any use of continuous glucose monitoring (CGM) to manage their diabetes during the
             course of the study

          -  Visually impaired

          -  Women who are pregnant, lactating or planning to become pregnant during the study
             period

          -  Diagnosed with any clinically significant condition (for example anemia, major organ
             system disease, infections, psychosis or cognitive impairment)

          -  Participant requires chronic steroid in adrenal suppressive doses, other
             immuno-modulatory medication or chemotherapy

          -  Participant is the investigator or any sub-investigator, general practitioner,
             practice staff, pharmacist, research assistant or other staff or relative of those
             directly involved in the conduct of the study and design of the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lena Borsa</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Montgomery</city>
        <state>Alabama</state>
        <zip>36105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ocean Springs</city>
        <state>Mississippi</state>
        <zip>39564</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68521</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pottstown</city>
        <state>Pennsylvania</state>
        <zip>19464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29223</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <zip>37620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <lastchanged_date>April 3, 2017</lastchanged_date>
  <firstreceived_date>November 6, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
